CD47-blocking checkpoint inhibitor TTI-621 shows promising results for cutaneous T-cell lymphomas
A novel CD47-blocking checkpoint inhibitor has shown promising interim results in a multicenter Phase I trail for relapsed/refractory mycosis fungoides and Szary syndrome, the most common types of cu...
Author: VJHemOnc
Added: 10/02/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Lymphoma | Mycosis Fungoides | T-cell Lymphoma